January 2018

Lynda Sutton, principle and cofounder of Cato BioVentures, a family owned venture capital of Cato Holdings, was recently featured in BioWorld's article titled, "Alternative to traditional venture capital money could fill translational gaps" by Jennifer Boggs, for her panel discussion at this year's January RESI conference featuring Cato BioVentures' innovative investment approaches in the healthcare sector:

"Cato Bioventures, for instance, started investing in gene therapy in 2000. "We're finally seeing early results," said Lynda Sutton, principal and co-founder.

Launched in 1988 as the venture capital affiliate of Cato Holding, a privately held family fund, has built a portfolio of firms, including those developing therapeutics, medical devices and stem cell therapies. It invests in firms at all stages of development and across multiple therapeutic areas, and its funds have gone into both public and private firms. Cato Bioventures offers a two-pronged approach to its investments, said Sutton, who, like de Souza, is another pharma veteran. The first is to look for technology "that needs a home, bring it in and form a company around it," with the aim of getting it to a value inflection point. The second involves looking for companies with good management, promising technology and invest money and resources to complement drug development efforts."

http://www.bioworld.com/content/alternative-traditional-venture-capital-money-could-fill-translational-gaps-0

October 2, 2017
Mallinckrodt plc (NYSE:MNK) today announced it has entered into a licensing agreement for development and commercialization of NeuroproteXeon's investigational, pharmaceutical-grade xenon gas for inhalation therapy being evaluated to improve survival and functional outcomes for patients resuscitated after a cardiac arrest. PDF

April 29, 2017
Cato Research and Cancer Advances Proudly Sponsors PurpleStride Raleigh-Durham 2017 PDF

May 10, 2016
Cancer Advances Proudly Sponsors PurpleStride Raleigh-Durham 2016 PDF

May 05, 2016
Manufacturing has begun for Cancer Advances' Lead Product PDF

March 28, 2016
NeuroproteXeon Appoints Cato Research for Phase III Trials

NeuroproteXeon Appoints Cato Research for Phase III Trials

Mervyn Maze, MB, ChB, Chief Medical Officer of NeuroproteXeon announced CATO Research of Durham, North Carolina as the Clinical Research Organization (CRO) administering the Company’s Phase III trial. Dr. Maze indicated the selection reflects CATO’s three decades of experience in international trial administration, their broad international scope, and the ease with which NP and CATO management interacted.

Present plans are for a nine country, approximately 30 sites, 1,300 patent trial, comparing hypothermia with hypothermia plus Xenon. The primary outcome will be survival from cardiac arrest. It is anticipated the trial will be complete in less than two years following FDA/ EMA approval of the Company’s IND application.

 

March 8, 2016
Cancer Advances attends PanCAN PDF

November 2, 2015
Join Cato BioVentures at BIO-Europe in Munich, Germany PDF

October 28, 2015
Cancer Advances Announces $48.5 Million Funding Commitment  PDF

June 15, 2015
Join Cato BioVentures at 2015 BIO International Convention PDF

May 15, 2015
Cancer Advances and Cato Research to Participate PurpleStride: Raleigh-Durham 2015 5K RUN & Family-Friendly Walk for Pancreatic Cancer Awareness and Research  PDF

January 15, 2015
Cancer Advances to attend ASCO Gastrointestinal Cancers Symposium PDF